Evaluation of the Safety, Tolerability and Immunogenicity of an Oral, Inactivated Whole
暂无分享,去创建一个
D. Sack | S. Chakraborty | H. Bloomberg | L. Dally | J. Bream | B. Denearing | L. V. D. Verg | J. Flores | Nicole Bauers | Clayton D. Harro | Richard I. Walker
[1] T. Farag,et al. Shigella Isolates From the Global Enteric Multicenter Study Inform Vaccine Development , 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[2] A. L. Bourgeois,et al. Development and Preclinical Evaluation of a Trivalent, Formalin-Inactivated Shigella Whole-Cell Vaccine , 2014, Clinical and Vaccine Immunology.
[3] Y. Takeda,et al. Protective immunity by oral immunization with heat‐killed Shigella strains in a guinea pig colitis model , 2013, Microbiology and immunology.
[4] Inacio Mandomando,et al. Burden and aetiology of diarrhoeal disease in infants and young children in developing countries (the Global Enteric Multicenter Study, GEMS): a prospective, case-control study , 2013, The Lancet.
[5] M. Levine,et al. Progress and pitfalls in Shigella vaccine research , 2013, Nature Reviews Gastroenterology &Hepatology.
[6] J. Bream,et al. Differential serum cytokine responses to inactivated and live attenuated seasonal influenza vaccines. , 2012, Cytokine.
[7] A. Naheed,et al. Decreasing Shigellosis-related Deaths without Shigella spp.–specific Interventions, Asia , 2010, Emerging infectious diseases.
[8] J. D. Di Santo,et al. Th17 Cells Are the Dominant T Cell Subtype Primed by Shigella flexneri Mediating Protective Immunity , 2010, The Journal of Immunology.
[9] E. Oaks,et al. Inactivated and subunit vaccines to prevent shigellosis , 2009, Expert review of vaccines.
[10] J. Crump,et al. Part II. Analysis of data gaps pertaining to Shigella infections in low and medium human development index countries, 1984–2005 , 2007, Epidemiology and Infection.
[11] D. Sack,et al. Increasing Spectrum in Antimicrobial Resistance of Shigella Isolates in Bangladesh: Resistance to Azithromycin and Ceftriaxone and Decreased Susceptibility to Ciprofloxacin , 2007, Journal of health, population, and nutrition.
[12] R. Walker,et al. Vaccine potential for inactivated shigellae. , 2007, Vaccine.
[13] M. Wolf,et al. Two Studies Evaluating the Safety and Immunogenicity of a Live, Attenuated Shigella flexneri 2a Vaccine (SC602) and Excretion of Vaccine Organisms in North American Volunteers , 2004, Infection and Immunity.
[14] M. Abreu,et al. Decreased Expression of Toll-Like Receptor-4 and MD-2 Correlates with Intestinal Epithelial Cell Protection Against Dysregulated Proinflammatory Gene Expression in Response to Bacterial Lipopolysaccharide1 , 2001, The Journal of Immunology.
[15] A. Trofa,et al. Dr. Kiyoshi Shiga: discoverer of the dysentery bacillus. , 1999, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[16] P. Sansonetti,et al. Vaccination against Shigellosis with Attenuated Shigella flexneri 2a Strain SC602 , 1999, Infection and Immunity.
[17] D. Mahalanabis,et al. Killed oral Shigella vaccine made from Shigella flexneri 2a protects against challenge in the rabbit model of shigellosis , 1999, Acta paediatrica.
[18] K. Schön,et al. Interferon‐γ receptor‐deficient mice exhibit impaired gut mucosal immune responses but intact oral tolerance , 1997, Immunology.
[19] J. Olson,et al. Characteristics of Shigella sonnei infection of volunteers: signs, symptoms, immune responses, changes in selected cytokines and acute-phase substances. , 1995, The American journal of tropical medicine and hygiene.
[20] S. Szu,et al. Perspective: hypothesis: serum IgG antibody is sufficient to confer protection against infectious diseases by inactivating the inoculum. , 1995, The Journal of infectious diseases.
[21] M. Levine,et al. Safety, immunogenicity, and efficacy in monkeys and humans of invasive Escherichia coli K-12 hybrid vaccine candidates expressing Shigella flexneri 2a somatic antigen , 1992, Infection and immunity.
[22] Y. Lerman,et al. Natural immunity to shigellosis in two groups with different previous risks of exposure to Shigella is only partly expressed by serum antibodies to lipopolysaccharide. , 1992, The Journal of infectious diseases.
[23] M. Levine,et al. Epidemiologic patterns of acute diarrhea and endemic Shigella infections in children in a poor periurban setting in Santiago, Chile. , 1991, American journal of epidemiology.
[24] A. Kantele. Antibody-secreting cells in the evaluation of the immunogenicity of an oral vaccine. , 1990, Vaccine.
[25] M. Levine,et al. Studies in volunteers to evaluate candidate Shigella vaccines: further experience with a bivalent Salmonella typhi-Shigella sonnei vaccine and protection conferred by previous Shigella sonnei disease. , 1990, Vaccine.
[26] D. Sack,et al. Cross-protection by B subunit-whole cell cholera vaccine against diarrhea associated with heat-labile toxin-producing enterotoxigenic Escherichia coli: results of a large-scale field trial. , 1988, The Journal of infectious diseases.
[27] T. L. Hale,et al. Serum immune response to Shigella protein antigens in rhesus monkeys and humans infected with Shigella spp , 1986, Infection and immunity.
[28] A. A. Reeder,et al. Antibody-dependent cell-mediated antibacterial activity: K lymphocytes, monocytes, and granulocytes are effective against shigella. , 1980, Journal of immunology.
[29] D. Swerdlow,et al. Global burden of Shigella infections: implications for vaccine development and implementation of control strategies. , 1999, Bulletin of the World Health Organization.
[30] M. Levine,et al. A modified Shigella volunteer challenge model in which the inoculum is administered with bicarbonate buffer: clinical experience and implications for Shigella infectivity. , 1995, Vaccine.
[31] A. Lindberg,et al. Serum IgG antibody responses to Shigella invasion plasmid-coded antigens detected by immunoblot. , 1994, Scandinavian journal of infectious diseases.
[32] H. Dupont,et al. Immunity in shigellosis. II. Protection induced by oral live vaccine or primary infection. , 1972, The Journal of infectious diseases.
[33] E. Gangarosa,et al. Studies on vaccination against bacillary dysentery. 6. Protection of children by oral immunization with streptomycin-dependent Shigella strains. , 1971, Bulletin of the World Health Organization.